Top

PharmacoEconomics

Published in:

01-10-2004 | Review Article

Changes in the costs of treating mental health disorders

An overview of recent research findings

Author: Ernst R. Berndt

Published in: PharmacoEconomics | Special Issue 2/2004

Abstract

This article reviews recent evidence on changes over time in the direct medical costs of treating three of the more common mental health disorders in the US: the acute (16-week) phase of major depressive disorder, the ongoing treatment of schizophrenia, and the ongoing treatment of bipolar I disorders. The three studies discussed in this article cover various time intervals over the decade from 1991 through 2000, and encompass both private sector and governmental funding sources. Although there has been a shift over time away from intensive psychosocial/psychotherapy and towards increasingly expensive psychopharmacotherapy for all three disorders, total direct medical costs of treatment for each of these three mental health disorders have been declining over time. However, a substantial portion of treatment is not supported by clinical evidence.

McKusick DT, Mark TL, King E, et al. Spending for mental health and substance abuse treatment, 1996. Health Affairs 1996; 17 (5): 147–57CrossRef

Duggan MG. Does Medicaid pay too much for prescription drugs? A case study of atypical antipsychotics. Cambridge (MA): National Bureau of Economic Research, 2003 Apr. Working Paper No. 9626

Croghan TW. The controversy of increased spending for antidepressants. Health Affairs 2001; 20 (2): 129–35PubMedCrossRef

Hanson KL. Public opinion and the mental health parity debate. Lessons from the survey literature. Psychiatric Serv 1998; 49 (8): 1059–66

Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and twelvemonth prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch Gen Psychiatry 1994; 51 (1): 8–19PubMedCrossRef

Keller MB, Berndt ER. Depression treatment. A life-long commitment? Psychopharmacol Bull 2002; 36 (2): 1–9

Berndt ER, Bir A, Busch SH, et al. The medical treatment of depression, 1991–1996. Productive inefficiency, expected outcome variations, and price indexes. J Health Econ 2002; 21: 373–96PubMedCrossRef

Frank RG, Busch SH, Berndt ER. Measuring prices and quantities of treatments for depression. Am Econ Rev 1998; 88 (2): 106–11

Frank RG, Berndt ER, Busch SH. Price indexes for the treatment of depression. In: Triplett JE, editor. Measuring the prices of medical treatments. Washington, DC: Brookings Institution Press, 1999: 72–102

10.

Berndt ER, Cutler DM, Frank RG, et al. Medical care prices and output. In: Newhouse JP, Culyer AC, editors. Handbook of health economics. Vol. 1A. Amsterdam: Elsevier Science BV, 2000: 119–80CrossRef

11.

Lehman AF. Quality of care in mental health. The case of schizophrenia. Health Aff 1999; 18 (5): 52–65CrossRef

12.

Lehman AF, Steinwachs DS. Translating research into practice. The schizophrenia patient outcomes research team (PORT) recommendations. Schizophr Bull 1998; 24 (1): 1–10PubMedCrossRef

13.

Lehman AF, Steinwachs DS, and the Survey Co-Investigators of the PORT Project. Patterns of usual care for schizophrenia. Initial results from the schizophrenia patient outcomes research team (PORT) client survey. Schizophr Bull 1998; 24 (1): 11–9PubMedCrossRef

14.

Frank RG, Berndt ER, Busch AB, et al. Quality-constant ‘prices’ for the ongoing treatment of schizophrenia. An exploratory study. Qtrly Rev Econ and Bus. 44 (3), July 2004: 390–409

15.

Rosenheck RA, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. A randomised controlled trial. JAMA 2003; 290 (20): 2693–702PubMedCrossRef

16.

Berndt ER. Trends and drivers of expenditures on psychotropic drugs in the US Presentation at the National Institute of Mental Health Pharmacoeconomics Research Workshop, Bethesda MD, 23 May 2002

17.

Frank RG, Conti R. Mental health policy and psychotropic drugs. Issue paper, Sub-Committee on Psychiatric Medications of the President’s Mental Health Commission. Washington, DC: 2004 Jan 24

18.

Ling DYC, Busch AB, Frank RG. Treatment price indexes for bipolar disorder [poster]. Presented at the National Institute of Mental Health, Economics of Mental Health Workshop; 2002 Sep 24; Bethesda. Updated, 8 July 2004

19.

American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 159 (4 Suppl.): 1–50

Title: Changes in the costs of treating mental health disorders
An overview of recent research findings
Author: Ernst R. Berndt
Publication date: 01-10-2004
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue Special Issue 2/2004
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200422002-00005

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in the costs of treating mental health disorders

An overview of recent research findings

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2004

The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation

The policy implications of gender mainstreaming for healthcare research in the EU

Concluding remarks

Impediments to the diffusion of innovative medicines in Europe

Are the economics of pharmaceutical research and development changing?

The impact of healthcare reform in The Netherlands